Drugs / NC525
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05787496 | Feb 2023 → Jan 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | NextCure, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05787496 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody specific for LAIR-1” NCT05787496 ↗ |
| Route | Intravenous | “Subjects received NC525 IV at 2mg/kg bi-weekly (Q2W) for Cycles 1-6, followed by every 4 weeks (Q4W) thereafter.” NCT05787496 ↗ |
| Target | LAIR1 | “Monoclonal antibody specific for LAIR-1” NCT05787496 ↗ |